Development and Validation of Educational Material for Guidance on the Use of Ribociclib Succinate in the Treatment of Advanced Breast Cancer

ABSTRACT

Introduction:  Cancer is considered a non-communicable chronic disease. Among women, breast cancer is the most common type, generating a significant economic impact on healthcare services. With the increasing incorporation of new technologies, such as cyclin-dependent kinase 4/6 (CDK4/6) inhibitors indicated for the oral treatment of locally advanced breast cancer, the role of the pharmacist has become even more relevant. Low adherence to the proposed therapeutic regimen, mainly due to adverse reactions, can increase the risk of disease progression. Therefore, pharmaceutical care during oncology treatment has become an important strategy to promote safe and effective pharmacotherapy.

Objective:  Develop and validate educational material to guide the use of ribociclib succinate in the treatment of breast cancer.

Method:  Initially, the educational material was developed considering content, language, and visual aspects. It was then evaluated by a panel of expert judges using the Delphi method. To measure the level of agreement, the Content Validity Index (CVI) was calculated using a Likert scale.

Results:  As a result, the booklet was considered validated, with a CVI score of 1.

Conclusion:  It is expected that this educational tool will support the correct and safe use of CDK4/6 inhibitors, promoting knowledge and improving patient adherence to treatment.

Key words:
Breast Neoplasms/drug therapy; Enzyme Inhibitors/therapeutic use; Cyclin-Dependent Kinase 4/therapeutic use; Cyclin-Dependent Kinase 6/therapeutic use; Patient Education Handout